Hester Biosciences Limited has informed the Exchange about Transcript
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences reported a mixed Q1 FY26 with standalone revenue at ₹63 crore, down 14% year-on-year, and standalone PAT declining 7%, mainly due to delayed government immunization orders (PPR and Lumpy Skin Disease vaccines) in the Animal Health division, which fell 33%. However, consolidated PAT more than doubled driven by a strong Africa turnaround — Hester Africa swung to a ₹5 crore profit on ₹17 crore revenue (vs ₹3 crore in Q1 FY25), supported by better commercial execution and stabilized Tanzania operations. Poultry Healthcare grew modestly at 2%, and Petcare showed early positive signals with repeat demand. Management highlighted that margins held steady despite top-line pressure, aided by cost control and better product mix, and expects a return to growth from Q2 onwards. The avian influenza vaccine launch is awaiting regulatory clearances expected this quarter.
Short-term standalone performance is weak due to deferred institutional orders, but the Africa turnaround and margin resilience are positive. Investors should watch for Q2 execution of delayed government tenders and the avian flu vaccine launch as near-term catalysts.